Division of Critical Care, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC; Department of Pediatrics, E-Da Hospital, I-Shou university, Kaohsiung, Taiwan, ROC.
Division of Critical Care, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC; Division of Neurology, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC.
J Formos Med Assoc. 2021 Jan;120(1 Pt 1):172-179. doi: 10.1016/j.jfma.2020.03.025. Epub 2020 Apr 16.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease associated with rapid clinical deterioration and the need for intensive care; therefore, it is essential to identify clinical parameters related to mortality and establish prognostic factors correlated with unfavorable outcome in high risk patients whose treatment may fail.
Between January 2004 and December 2018, a total of 51 pediatric patients (less than 18 years old) who fulfilled the diagnostic criteria of HLH-2004 with documented results of bone marrow investigations at Kaohsiung Chang Gung Memorial Hospital were enrolled. The treatment protocol was based on hemophagocytic lymphohistiocytosis-94 (HLH-94) and HLH-2004. We retrospectively reviewed electronic medical records (EMR) including clinical features, length of intensive care unit (ICU) stay, serological tests, microscopic reports of bone marrow examination, and ultrasound examination reports at diagnosis to identify prognostic factors. The patients were divided into four groups based on etiology; these included infection associated hemophagocytic syndrome (IAHS), macrophage activation syndrome (MAS), malignancy associated hemophagocytic lymphohistiocytosis (MA-HLH), and idiopathic hemophagocytic lymphohistiocytosis (IHLH) to identify differences among the groups.
Out of 51 patients enrolled, 27 patients had IAHS, 12 MAS, 8 MA-HLH, and 4 IHLH. The median age at diagnosis was 7 years. The overall mortality rate was 15.7% (there was no mortality in the MA-HLH group); the mean length of ICU stay was 6 ± 20.8 days. Longer activated partial thromboplastin time (aPTT) (p = 0.007), lower sodium concentration (p = 0.0007), and higher creatinine (p = 0.032) and aspartate aminotransferase (AST) (p = 0.017) were significantly related to mortality. Multivariate Cox regression analysis demonstrated that aPTT (p = 0.045, HR = 1.03, 95% CI = 1.0-1.1) was an independent risk factor for mortality. The receiver operating characteristic (ROC) curve showed that aPTT longer than 44.35 s was the cutoff value predicting mortality, with a sensitivity and specificity of 72% and 66.7%, respectively.
MA-HLH had the lowest mortality rate, as most children died from the underlying malignant disease and not from HLH. Impaired liver and renal functions were related to mortality. Prolonged aPTT > 44.35 s is a strong predictive factor for mortality.
噬血细胞性淋巴组织细胞增生症(HLH)是一种危及生命的疾病,与快速临床恶化和需要重症监护有关;因此,识别与死亡率相关的临床参数并建立与高危患者不良预后相关的预后因素至关重要,这些患者的治疗可能会失败。
2004 年 1 月至 2018 年 12 月,在高雄长庚纪念医院进行骨髓检查并记录结果的 51 名符合 HLH-2004 诊断标准的儿科患者(年龄小于 18 岁)入组。治疗方案基于噬血细胞性淋巴组织细胞增生症-94(HLH-94)和 HLH-2004。我们回顾性分析了电子病历(EMR)中的临床特征、重症监护病房(ICU)住院时间、血清学检查、骨髓检查显微镜报告和诊断时的超声检查报告,以确定预后因素。根据病因将患者分为四组:感染相关噬血细胞综合征(IAHS)、巨噬细胞活化综合征(MAS)、恶性肿瘤相关噬血细胞性淋巴组织细胞增生症(MA-HLH)和特发性噬血细胞性淋巴组织细胞增生症(IHLH),以确定组间差异。
51 名入组患者中,27 名患者为 IAHS,12 名患者为 MAS,8 名患者为 MA-HLH,4 名患者为 IHLH。诊断时的中位年龄为 7 岁。总死亡率为 15.7%(MA-HLH 组无死亡);ICU 住院时间平均为 6±20.8 天。较长的活化部分凝血活酶时间(aPTT)(p=0.007)、较低的钠浓度(p=0.0007)、较高的肌酐(p=0.032)和天门冬氨酸氨基转移酶(AST)(p=0.017)与死亡率显著相关。多变量 Cox 回归分析表明,aPTT(p=0.045,HR=1.03,95%CI=1.0-1.1)是死亡率的独立危险因素。受试者工作特征(ROC)曲线显示,aPTT 大于 44.35s 是预测死亡率的截断值,敏感性和特异性分别为 72%和 66.7%。
MA-HLH 的死亡率最低,因为大多数儿童死于基础恶性疾病,而不是 HLH。肝肾功能受损与死亡率相关。延长的 aPTT>44.35s 是死亡的有力预测因子。